Group-Sequential Methods for Adaptive Seamless Phase II/III Clinical Trials

By Stallard Nigel  

Journal of Biopharmaceutical Statistics, Vol. 21, Iss. 4, 2011-07 ,pp. : 787-801

Taylor & Francis Ltd

Access to resources Recommend Favorite

The Type II Error Probability of a Group Sequential Test of Efficacy and Futility, and Considerations for Power and Sample Size

By Dobbins Thomas W.  

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 2, 2013-03 ,pp. : 378-393

Taylor & Francis Ltd

Access to resources Recommend Favorite

Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: A North Central Cancer Treatment Group trial

By Galanis Evanthia   Buckner Jan   Maurer Matthew   Reid Joel   Kuffel Mary   Ames Matthew   Scheithauer Bernd   Hammack Julie   Pipoly George   Kuross Steven  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 495-503

Springer Publishing Company

Access to resources Recommend Favorite

Phase II Study of Interferon Gamma in Malignant Carcinoid Tumors (E9292): A Trial of the Eastern Cooperative Oncology Group

By Stuart Keith   Levy Donna E.   Anderson Tom   Axiotis Constantine A.   Dutcher Janice P.   Eisenberg Andrew   Erban John K.   Benson III Al Bowen  

Investigational New Drugs, Vol. 22, Iss. 1, 2004-01 ,pp. : 75-81

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: A Southwest Oncology Group study

By Whitehead Robert   McCoy Sheryl   Macdonald John   Rivkin Saul   Neubauer Marcus   Dakhil Shaker   Lenz Heinz-Josef   Tanaka Michael   Abbruzzese James  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 335-341

Springer Publishing Company

Access to resources Recommend Favorite